165 related articles for article (PubMed ID: 29951984)
21. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Hurmuzlu M; Monge OR; Smaaland R; Viste A
Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
[TBL] [Abstract][Full Text] [Related]
22. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score.
Matsuda S; Takeuchi H; Kawakubo H; Fukuda K; Nakamura R; Takahashi T; Wada N; Saikawa Y; Omori T; Kitagawa Y
Ann Surg Oncol; 2015 Jan; 22(1):302-10. PubMed ID: 24952029
[TBL] [Abstract][Full Text] [Related]
23. Subjective global assessment and prealbumin levels of esophageal cancer patients undergoing concurrent chemoradiotherapy.
Pan P; Tao G; Sun X
Nutr Hosp; 2015 May; 31(5):2167-73. PubMed ID: 25929389
[TBL] [Abstract][Full Text] [Related]
24. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
25. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
26. Albumin and Derived Neutrophil-to-Lymphocyte Ratio is a Novel Prognostic Factor for Patients with Esophageal Squamous Cell Carcinoma.
Abe T; Oshikiri T; Goto H; Kato T; Horikawa M; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Nakamura T; Kakeji Y
Ann Surg Oncol; 2022 Oct; 29(11):6860-6866. PubMed ID: 35622180
[TBL] [Abstract][Full Text] [Related]
27. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
28. Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion.
Hamai Y; Hihara J; Emi M; Taomoto J; Aoki Y; Kishimoto I; Ibuki Y; Okada M
Anticancer Res; 2013 Aug; 33(8):3495-502. PubMed ID: 23898125
[TBL] [Abstract][Full Text] [Related]
29. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
30. Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy.
Lee HJ; Kim JM; Chin YJ; Chong GO; Park SH; Lee YH; Hong DG; Lee YS
Anticancer Res; 2020 Jan; 40(1):451-458. PubMed ID: 31892600
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
[TBL] [Abstract][Full Text] [Related]
32. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
33. Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients.
Nam SY; Jeon SW; Lee SJ; Kwon YH; Lee HS; Kim SK
Gut Liver; 2020 Jul; 14(4):450-458. PubMed ID: 32000467
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Wu CE; Lin YC; Hong JH; Chuang CK; Pang ST; Liaw CC
Anticancer Res; 2013 Jun; 33(6):2605-10. PubMed ID: 23749915
[TBL] [Abstract][Full Text] [Related]
35. Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer.
Di Fiore A; Lecleire S; Gangloff A; Rigal O; Benyoucef A; Blondin V; Sefrioui D; Quiesse M; Iwanicki-Caron I; Michel P; Di Fiore F
Dig Liver Dis; 2014 Mar; 46(3):270-5. PubMed ID: 24439424
[TBL] [Abstract][Full Text] [Related]
36. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
38. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
39. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
[TBL] [Abstract][Full Text] [Related]
40. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
Huang YH; Hung YS; Lai CC; Ho MM; Yeh KY; Yang C; Lu CH; Tseng CK; Tsang NM; Hung CY; Hsueh SW; Chang PH; Ho YW; Lin YC; Chou WC
Anticancer Res; 2021 Oct; 41(10):5213-5222. PubMed ID: 34593474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
